CEO
Bristol Myers CEO: America’s Biopharma Leadership Not Guaranteed
Bristol Myers Squibb; CEO; Chris Boerner; biopharma; Americas; global competitiveness; dealmaking; innovation; growth portfolio
Galapagos Walks Back Split Plans, Raising Questions Over Cell Therapy Assets
Galapagos; company split; cell therapy; spinoff; CEO appointment; biotech industry; CAR T business
UnitedHealth Group CEO Andrew Witty Steps Down; Stephen Hemsley Returns as CEO
UnitedHealth Group; Andrew Witty; Stephen Hemsley; CEO transition; leadership change; personal reasons; financial guidance suspension; stock drop
Fortrea CEO Steps Down Amid Continued Stock Decline Post-Labcorp Spinout
Fortrea; Labcorp; CEO departure; stock decline; CRO spinout; leadership change; clinical trials; public company
Brian Armstrongs NewLimit raises a $130M Series B, laying out road map for anti-aging drugs
NewLimit, Brian Armstrong, Coinbase CEO, anti-aging drugs, epigenetic reprogramming, Series B funding, Kleiner Perkins, genetic cell programming, healthy lifespan extension
Alcon Secures Control of Aurion Biotech in Strategic Takeover
Alcon, Aurion Biotech, majority stake, CEO replacement, cell therapy, corneal endothelial disease, AURN001, IPO dispute
23andMe files for bankruptcy as CEO Anne Wojcicki steps down to become bidder
Bankruptcy, CEO, Anne, Customer
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash
Nimbus Therapeutics Announces Leadership Transition: Abbas Kazimi Appointed as New CEO
Nimbus Therapeutics, CEO transition, Abbas Kazimi, Jeb Keiper, biotechnology, computational drug discovery